- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05257343
Efficacy of a Low Dose, Oral, Liquid Iron Supplement on Restoring Inadequate Blood Iron to Normal Levels
Assessment of the Efficacy of a Low-Dose Iron Supplement in Restoring Iron Levels to Normal Range Without Promoting Constipation or Adverse Gastrointestinal Effects Among Healthy Premenopausal Women With Iron Deficiency Without Anemia
Study Overview
Status
Conditions
Detailed Description
This is a randomized, double-blind, placebo-controlled, 8-week intervention clinical study assessing the safety and efficacy of a new low-dose liquid iron supplement in restoring iron levels to normal ranges without promoting constipating side-effects among healthy premenopausal women with non-anemic iron deficiency.
A total of 82 premenopausal female subjects over the age of 18 years old are planned for this study. Enrolled subjects will be assigned a unique study number in the 100 series as the subject ID for the study to maintain anonymity. The subject ID will be assigned in sequential order starting with 101 (i.e., 101, 102, 103, etc). After signing the informed consent document, enrolled subjects will be screened, and qualifying subjects will be randomly assigned to one of two groups (Group A or Group B) depending on the treatment (liquid iron supplement or placebo). Following random assignment, subjects will revisit the laboratory to complete baseline testing for primary, secondary, and exploratory outcomes. After 4 weeks of daily supplementation of their respective randomly assigned condition, subjects return to the laboratory for reassessment of secondary outcomes. The last laboratory visit will occur following 8 weeks of daily supplementation in which subjects will be reassessed on all outcomes in a manner identical to baseline.
GROUPS:
- Group A: Single-dose containing 10 mL of a liquid iron formulation to be ingested once a day on an empty stomach no sooner than 3 hours after consuming a meal.
- Group B: Single-dose containing 10 mL of the placebo formulation to be ingested once a day on an empty stomach no sooner than 3 hours after consuming a meal.
VISITS:
- Visit 1: Study enrollment and eligibility screening. Written informed consent will be obtained to confirm study enrollment prior to eligibility screening.
- Visit 2: Baseline assessment
- Visit 3: Reassess secondary variables only
- Visit 4: Reassess all measurements for final post-testing and end of study (EOS).
For laboratory visits requiring blood donation (visits 1, 2, and 4), subjects will arrive at the laboratory following an overnight fast (≥ 10 hours) and undergo standard sterile venipuncture techniques by a certified phlebotomist. Blood samples, approximately 10mL in volume, will be collected into a marble top (gel-barrier) tube interiorly coated with silicone. Following collection, samples will be inverted 4-6 times then stored upright at room temperature in a test tube holder for approximately 30 minutes to promote coagulation; thereafter, samples will be centrifuged for serum separation. The resulting serum aliquot will be immediately stored at -80°C until further analysis of blood chemistry variables.
For questionnaire assessments (Patient assessment of constipation - symptoms, functional bowel index, Gastrointestinal symptom rating scale, and abbreviated Profile of Mood States), subjects will complete the questionnaires in isolation in a quiet room isolated to avoid bystander influence. For visit 3, subjects are not required to be fasted. All study visits will be conducted at the same time of day (± 1 hour).
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Florida
-
Tampa, Florida, United States, 33607
- The Applied Science and Performance Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Healthy female subjects > 18 years old
- Premenopausal (experiencing regular menstrual cycles)
- Hemoglobin > 11g/dL
- Serum ferritin < 70 ng/mL
- hs-CRP < 3 mg/L
- BMI 18 - 29.9 kg/m2
- No intake of dietary supplements containing iron 30 days prior to enrollment
- Willing and able to give written informed consent
- Able to read, understand, sign and date the informed consent document (English only)
- Able and willing to comply with the schedule visit(s) and study requirements.
Exclusion Criteria:
- Currently taking (within the past 14 days) dietary supplements including, vitamins (any), minerals, protein shakes, vitamin water, other supplements
- History of gastrointestinal disorders that could lead to uncertain absorption of the study supplements, (i.e., inflammatory bowel disease, ulcerative colitis, Crohn's disease, colostomy, or eating disorder)
- History or current malignancy
- Receiving chemotherapy agents or radiation treatments
- Prior health issues showing high CRP or other inflammatory markers
- Pregnancy or has breast fed within 3 months prior to enrollment
- BMI <18 or >25 kg/m2
- Diagnosis of a terminal illness
- Use of prescription medications that impact digestion (i.e., proton pump inhibitor medications, other)
- History of alcohol abuse
- History or current drug abuse
- History or current cigarette smoke (including vaping) within the past 14 days from the screening visit
- Insulin-dependent diabetes and/or metformin use
- Chronic kidney or liver disease
- Anemia
- Has significant concurrent illnesses (controlled or uncontrolled), such as diabetes, lupus, epilepsy, or cardiac disorders, hepatitis B/C, HIV, serious mental health illness such as dementia or schizophrenia; psychiatric hospitalization in the past two years, or other, which in the opinion of the investigator, such condition might be aggravated as a result of treatment
- The investigator feels that for any reason the subject is not eligible to participate in the study
- Use within 24 hours preceding enrollment of ibuprofen, acetaminophen, any other analgesics, anti-inflammatory products, or any products including herbals and supplements that could interfere with the clinical assessments of this study (other than drugs used for anesthesia)
- History of uncontrolled cardiovascular disease (i.e., myocardial infarction, hypertension, hypercholesterolemia, peripheral vascular disease, other)
- History, or current bleeding disorders (i.e., hemophilia or von Willebrand disease), or anticipated treatment with prescription anticoagulants
- Developmental disability or cognitive impairment that would preclude adequate comprehension of the informed consent form and/or ability to follow study subject requirement and/or record the necessary study measurements
- A family member of the investigator or an employee of the investigator
- Participation in any other investigational study within 30 days prior to consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Daily dose (10 mL) of a visually identical liquid placebo supplement to be ingested on an empty stomach no sooner than 3 hours after consuming a meal.
|
8-weeks of supplementing with a visually identical liquid placebo supplement.
|
Experimental: Blood Builder Treatment
Daily dose (10 mL) of liquid iron supplement (Blood Builder®) formulation to be ingested on an empty stomach no sooner than 3 hours after consuming a meal.
|
8-weeks of supplementing with a liquid iron supplement (Blood Builder ®)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serum Iron
Time Frame: Week 0 and Week 8
|
Changes in Iron in fasted serum blood samples.
|
Week 0 and Week 8
|
Serum Ferritin
Time Frame: Week 0 and Week 8
|
Changes in Ferritin in fasted serum blood samples.
|
Week 0 and Week 8
|
Total Iron-Binding Capacity (TIBC)
Time Frame: Week 0 and Week 8
|
Changes in TIBC in fasted serum blood samples.
|
Week 0 and Week 8
|
Transferrin Saturation (tSAT)
Time Frame: Week 0 and Week 8
|
Changes in tSAT in fasted serum blood samples.
|
Week 0 and Week 8
|
Complete Blood Count (CBC)
Time Frame: Week 0 and Week 8
|
Changes in complete blood count with differential will be assessed via fasted serum blood samples
|
Week 0 and Week 8
|
High Sensitivity C-Reactive Protein (hs-CRP)
Time Frame: Week 0 and Week 8
|
Changes in hs-CRP in fasted serum blood samples.
|
Week 0 and Week 8
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient Assessment of Constipation - Symptoms Questionnaire
Time Frame: Week 0, Week 4, and week 8
|
Changes assessed by administering the Patient Assessment of Constipation - Symptoms questionnaire for subjective assessment of constipation symptoms.
Each question is answered from 0 (no symptoms at all) to 4 (severe symptoms).
The lower the mean score, the less severe the symptoms.
The higher the mean score, the more severe the symptoms.
|
Week 0, Week 4, and week 8
|
Functional Bowel Index
Time Frame: Week 0, Week 4, and week 8
|
Changes assessed by administering the Functional Bowel Index for subjective assessment of bowel movements.
A 3 item questionnaire scored from 0-100 with higher scores indicating greater severity and scores higher than 28.8 points indicating constipation.
|
Week 0, Week 4, and week 8
|
Gastrointestinal symptom rating scale
Time Frame: Week 0, Week 4, and week 8
|
Changes assessed by administering the Gastrointestinal Symptom Rating Scale for subjective assessment of gastrointestinal symptoms and their severity.
It is a 15-item questionnaire designed to assess the symptoms associated with common GI disorders.
It has 5 subscales (Reflux, Diarrhea, Constipation, Abdominal Pain, and Indigestion Syndrome).
Subscale scores range from 1 to 7 and higher scores represent more discomfort, and lower scores represent less or even no discomfort.
|
Week 0, Week 4, and week 8
|
Abbreviated Profile of Mood States
Time Frame: Week 0 and Week 8
|
Changes assessed in the abbreviated profile of mood states for subjective assessment of the subject's mood and overall well-being.
It is a 40 point scale, divided into 7 different subscales, with a 5 point Likert scale, ranging from 0 (not at all) to 4 (Extremely) of how a subject feels in response to that particular feeling.
The following equation is used to determine the overall score: Total Mood Disturbance = [Tension+Depression+Anger+Fatigue+Confusion] - [Vigor+Esteem Related Affect].
A lower score indicates overall better mood, while a lower score indicates worse overall mood.
|
Week 0 and Week 8
|
Adverse Events
Time Frame: Week 0, Week 4, and Week 8
|
Defined as participants self-reported adverse effects.
Items that will be surveyed are headache, dizziness, nausea, vomiting, indigestion, blurred vision, lethargy, swelling, itching, chest pain, heart palpitations, difficulty breathing, lethargy, and muscle cramps.
|
Week 0, Week 4, and Week 8
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Body Composition via Body Fat Percentage
Time Frame: Week 0 and Week 8
|
Changes assessed in body fat percentage via Dual X-Ray Absorptiometry.
|
Week 0 and Week 8
|
Bone Mineral Density
Time Frame: Week 0 and Week 8
|
Changes assessed in bone mineral density in grams via Dual X-Ray Absorptiometry.
|
Week 0 and Week 8
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MF121521
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Iron Deficiency (Without Anemia)
-
Swiss Federal Institute of TechnologyUnited States Agency for International Development (USAID); Quadram Institute... and other collaboratorsCompletedIron-deficiency | Iron Deficiency Anemia | Iron Deficiency (Without Anemia)Peru
-
King's CollegeCompletedIron-deficiency | Iron Deficiency Anemia | Iron Deficiency (Without Anemia)United States
-
Cornell UniversityCompletedIron Deficiency (Without Anemia)United States
-
University of MinnesotaUniversity of HawaiiCompletedIron-deficiency | Iron Deficiency Anemia | Iron Deficiency (Without Anemia)United States
-
University of ZurichCompletedIron Deficiency (Without Anemia)Switzerland
-
Pierre-Alexandre KrayenbuehlCompletedIron Deficiency (Without Anemia)Switzerland
-
Cornell UniversityInstituto Nacional de Salud Publica, MexicoCompletedIron Deficiency (Without Anemia)United States
-
Cornell UniversityCompletedIron Deficiency Without AnemiaChina
-
Auerbach Hematology Oncology Associates P CMedStar Women's Care at HoneygoCompletedPregnancy | Iron Deficiency (Without Anemia)United States
-
University of WestminsterGencor Pacific GroupCompletedIron Deficiency (Without Anemia)United Kingdom
Clinical Trials on Liquid Placebo Supplementation
-
MARCELLUS SIMADIBRATACompletedMalnutrition | Nutritional Status | Body Mass Index | Nutrition Assessment | Hand Strength | HospitalIndonesia
-
Super Inspired LLCRecruitingArthropathy of Knee | Arthropathy of HipUnited States
-
McMaster UniversityQueen's UniversityRecruitingObesity | Non-Bariatric Surgery | Preoperative Weight Loss | Preoperative OptimizationCanada
-
Uppsala UniversityVästmanland County Council, SwedenCompleted
-
Charite University, Berlin, GermanyFreie Universität Berlin, Institute of Biology/Genetic, Berlin,Germany; Karl-Franzens-Universität...CompletedSubjective Cognitive DeclineGermany
-
University of TaipeiCompletedAnthropometry | Cardiorespiratory Fitness | MetabolismTaiwan
-
Slovak Academy of SciencesNational Cheng Kung University; Comenius University; University Hospital BratislavaUnknownParkinson Disease | Healthy Volunteers | Mild Cognitive Impairment | Subjective Cognitive ImpairmentSlovakia, Taiwan
-
Universidad de MurciaUniversidad Francisco de VitoriaCompleted
-
Medical University of GdanskNutricia FoundationCompleted
-
Bionos Biotech S.L.CompletedHealthy VolunteersSpain